Morgan Stanley
XFOR icon

Morgan Stanley’s X4 Pharmaceuticals XFOR Stock Holding History

Morgan Stanley’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.1M Buy
9,466,992
+1,258,977
+15% +$4.72M ﹤0.01% 2336
2025
Q4 		$32.8M Buy
8,208,015
+8,204,287
+220,072% +$29.8M ﹤0.01% 2490
2025
Q3 		$12.8K Sell
3,728
-7,196
-66% -$18.6K ﹤0.01% 6830
2025
Q2 		$20.8K Sell
10,924
-8,076
-43% -$33.1K ﹤0.01% 6638
2025
Q1 		$135K Buy
19,000
+650
+4% +$8.95K ﹤0.01% 5883
2024
Q4 		$404K Buy
18,350
+1,995
+12% +$31.8K ﹤0.01% 5509
2024
Q3 		$328K Buy
16,355
+8,710
+114% +$182K ﹤0.01% 5574
2024
Q2 		$133K Sell
7,645
-39,236
-84% -$1.28M ﹤0.01% 5857
2024
Q1 		$1.95M Buy
46,881
+20,123
+75% +$560K ﹤0.01% 4595
2023
Q4 		$673K Buy
26,758
+18,700
+232% +$455K ﹤0.01% 5491
2023
Q3 		$264K Buy
8,058
+1,430
+22% +$62.4K ﹤0.01% 5454
2023
Q2 		$386K Buy
6,628
+4,088
+161% +$210K ﹤0.01% 5346
2023
Q1 		$66.3K Buy
2,540
+5
+0.2% +$147 ﹤0.01% 6172
2022
Q4 		$75.5K Buy
2,535
+627
+33% +$29.7K ﹤0.01% 6104
2022
Q3 		$97K Buy
1,908
+1,802
+1,700% +$62.3K ﹤0.01% 6092
2022
Q2 		$3K Sell
106
-191
-64% -$7.27K ﹤0.01% 7532
2022
Q1 		$16K Sell
297
-105
-26% -$6.02K ﹤0.01% 7241
2021
Q4 		$27K Buy
402
+109
+37% +$13.8K ﹤0.01% 7098
2021
Q3 		$46K Sell
293
-48
-14% -$7.9K ﹤0.01% 6764
2021
Q2 		$67K Buy
341
+237
+228% +$59.6K ﹤0.01% 6537
2021
Q1 		$27K Sell
104
-632
-86% -$166K ﹤0.01% 6615
2020
Q4 		$142K Buy
736
+175
+31% +$34.4K ﹤0.01% 5768
2020
Q3 		$114K Sell
561
-163
-23% -$39.1K ﹤0.01% 5366
2020
Q2 		$202K Buy
724
+589
+436% +$161K ﹤0.01% 5072
2020
Q1 		$41K Sell
135
-508
-79% -$144K ﹤0.01% 5549
2019
Q4 		$206K Buy
643
+426
+196% +$153K ﹤0.01% 5400
2019
Q3 		$83K Buy
217
+104
+92% +$41.2K ﹤0.01% 5511
2019
Q2 		$50K Buy
113
+97
+606% +$49.3K ﹤0.01% 5608
2019
Q1 		$8K Sell
16
-41
-72% -$22.6K ﹤0.01% 6238
2018
Q4 		$23K Sell
57
-17
-23% -$6.49K ﹤0.01% 5987
2018
Q3 		$22K Buy
74
+19
+35% +$8.06K ﹤0.01% 6111
2018
Q2 		$36K Sell
55
-3
-5% -$9.82K ﹤0.01% 5998
2018
Q1 		$237K Buy
+58
New +$169K ﹤0.01% 5400
2017
Q4 		– Hold
0
– – – 6664

Other funds holding XFOR

EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley's XFOR Position: Q1 2026 in Review

Morgan Stanley increased its X4 Pharmaceuticals (XFOR) stake by 15% in Q1 2026, buying an estimated $4.72M and bringing the position to 9,466,992 shares worth $39.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Morgan Stanley first reported a position in XFOR in Q1 2018 and has held it in 33 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Morgan Stanley held 9,466,992 shares of X4 Pharmaceuticals worth $39.1M as of Q1 2026.
  • Morgan Stanley bought 1,258,977 X4 Pharmaceuticals shares in Q1 2026, an estimated $4.72M.
  • X4 Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2336 holding.
  • Morgan Stanley first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.